Fixed-Duration
AstraZeneca’s Calquence Combination Shows Promise in Chronic Lymphocytic Leukemia with Fixed-Duration Regimens
AstraZeneca, Calquence, chronic lymphocytic leukemia, CLL, fixed-duration treatment, acalabrutinib, venetoclax, obinutuzumab, AMPLIFY trial
AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice
AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment